X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SHASUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SHASUN PHARMA DIVIS LABORATORIES/
SHASUN PHARMA
 
P/E (TTM) x 34.1 123.9 27.5% View Chart
P/BV x 6.6 8.5 77.7% View Chart
Dividend Yield % 0.7 0.2 290.2%  

Financials

 DIVIS LABORATORIES   SHASUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
SHASUN PHARMA
Mar-14
DIVIS LABORATORIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,14294 1,212.1%   
Low Rs53346 1,169.1%   
Sales per share (Unadj.) Rs146.6214.2 68.4%  
Earnings per share (Unadj.) Rs33.05.3 619.1%  
Cash flow per share (Unadj.) Rs38.415.8 242.8%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.21.4 83.5%  
Book value per share (Unadj.) Rs222.853.3 417.7%  
Shares outstanding (eoy) m265.4756.62 468.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.70.3 1,750.5%   
Avg P/E ratio x25.313.1 193.5%  
P/CF ratio (eoy) x21.84.4 493.5%  
Price / Book Value ratio x3.81.3 286.8%  
Dividend payout %30.318.7 161.5%   
Avg Mkt Cap Rs m222,3183,958 5,617.3%   
No. of employees `00010.8NA-   
Total wages/salary Rs m4,5612,164 210.8%   
Avg. sales/employee Rs Th3,616.0NM-  
Avg. wages/employee Rs Th423.8NM-  
Avg. net profit/employee Rs Th814.9NM-  
INCOME DATA
Net Sales Rs m38,91512,127 320.9%  
Other income Rs m1,134229 494.6%   
Total revenues Rs m40,04912,356 324.1%   
Gross profit Rs m12,6171,009 1,250.4%  
Depreciation Rs m1,425594 240.0%   
Interest Rs m13415 3.2%   
Profit before tax Rs m12,313230 5,360.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543-73 -4,872.4%   
Profit after tax Rs m8,770302 2,902.9%  
Gross profit margin %32.48.3 389.7%  
Effective tax rate %28.8-31.7 -90.9%   
Net profit margin %22.52.5 904.6%  
BALANCE SHEET DATA
Current assets Rs m45,3516,884 658.8%   
Current liabilities Rs m6,5078,456 77.0%   
Net working cap to sales %99.8-13.0 -770.2%  
Current ratio x7.00.8 856.0%  
Inventory Days Days12762 205.6%  
Debtors Days Days95108 88.5%  
Net fixed assets Rs m21,1604,970 425.7%   
Share capital Rs m531113 468.6%   
"Free" reserves Rs m58,6252,875 2,039.2%   
Net worth Rs m59,1563,020 1,958.7%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m67,83213,347 508.2%  
Interest coverage x926.81.6 59,665.0%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.9 63.1%   
Return on assets %12.95.4 241.0%  
Return on equity %14.810.0 148.2%  
Return on capital %20.813.3 156.4%  
Exports to sales %046.4 0.0%   
Imports to sales %21.814.2 153.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m8,4851,728 491.1%   
Fx inflow Rs m32,3595,843 553.8%   
Fx outflow Rs m9,0422,173 416.1%   
Net fx Rs m23,3173,669 635.4%   
CASH FLOW
From Operations Rs m7,759398 1,951.4%  
From Investments Rs m-4,783-1,635 292.5%  
From Financial Activity Rs m-3,1421,309 -240.1%  
Net Cashflow Rs m-16671 -233.1%  

Share Holding

Indian Promoters % 52.0 39.2 132.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.6 327.8%  
FIIs % 19.0 17.6 108.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 39.6 43.4%  
Shareholders   31,796 20,750 153.2%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 11, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - NOVARTIS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS